Skip to main content
Logo Logo Logo
  • Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Investors

    Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals

    Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients

    Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers

    Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links

    Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us

    Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up

Our News

Share this:

Supporting Newcomer Entrepreneurs - Forward·Inc’s Challengers Pitch Competition

July 13, 2025

Alnylam’s Challengers is our social impact initiative that aims to improve health and well-being by rallying behind fearless Challengers – bold leaders, navigators, and guides – increasing access to personalized care and support for underserved communities.

As part of our ongoing commitment to support refugees and displaced individuals in rebuilding their futures, we were recently privileged to sponsor our Challengers partner Forward·Inc's inaugural Challengers Pitch Competition.

Based in the Netherlands, Forward·Inc helps newcomers establish themselves in employment and become economically self-sufficient, with a particular focus on individuals who have been forcibly displaced and cannot return to their home countries.

The Challengers Pitch Competition was a dynamic ‘Dragon’s Den / Shark Tank’ type process, designed to support more established newcomer entrepreneurs’ start-up ambitions. With bespoke resources, expertise and counsel, the candidates were helped in refining their business plans and investor pitches, with a view to securing onward funding and expansion.

The candidates’ business plans spanned a rich variety of sectors and topics, including an AI property rental platform, SME optimisation tool, multi-dweller property subscription service, digital business cards for physicians, digital platform connecting chefs, culturally-driven condiment brand, multi-cultural food ‘shopateria’, and botanical water-flavouring sachets.

Many of the business plans were grounded in the need for simpler solutions to practical problems experienced by newcomers and the commonly-shared quest to source the nostalgic tastes of home. You can see each of their topline profiles here.

Each of the candidates was matched with a mentor from across the Alnylam network to help them practice and refine their plans and pitches. Eight took part in the semi-final, held at Alnylam Netherlands on 22nd May with our Netherlands Finance Director, Kevin Springer, as one of the judges. Six candidates then progressed to the final, held on 19th June at the Forward·Inc Festival in Amsterdam, with Christian Downton, Country Manager of Alnylam Netherlands, as a judge.

The Forward·Inc Festival was a vibrant celebration of multiculturalism and entrepreneurship and an inspiring display of the incredible achievements of newcomers from around the world who have made their mark on the Netherlands and beyond. It also provided the ideal networking forum for the candidates to build their connections with investors and other business owners.

After a series of very strong final pitches, and much discussion by the judges, Layth Massoud of Fil Foods was announced as the winner, for his modern take on elevating Palestinian chilli shatta into a versatile portfolio of hot sauce products with a socially conscious approach.

Layth, of Fil Foods, receiving his €10,000 prize from Christian Downton and the other Competition judges

Supporting organisations like Forward·Inc is central to our Alnylam values and our commitment to corporate responsibility. We look forward to seeing each one of these businesses flourish.

 

Tags

Responsibility, Articles, Alnylam Challengers, Forward Inc.

Related Content See All News ›
Responsibility Alnylam Recognized by Newsweek as One of America’s Most Responsible Companies for the ...
Responsibility Alnylam Challengers: Empowering Frontline Care for Underserved Communities in Boston
Responsibility Everest and Everything In Between: A Journey Back to Nepal

Share this:

Categories

  • Leadership
  • Perspectives
  • RNAi
  • Patient Focus
  • Responsibility
  • Careers & Culture

Content Types

  • Articles
  • Podcasts
  • Presentations
  • Videos
See All News ›
Related Content See All News ›
Responsibility Alnylam Recognized by Newsweek as One of America’s Most Responsible Companies for the ...
Responsibility Alnylam Challengers: Empowering Frontline Care for Underserved Communities in Boston
Responsibility Everest and Everything In Between: A Journey Back to Nepal
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

  • Our Company
  • Our Science
  • Our Products
  • Our News
  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers
  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates
  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map
  • Sign Up For Updates

Copyright ©  Alnylam Pharmaceuticals, Inc. — All Rights Reserved

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site